Skip to main content
Premium Trial:

Request an Annual Quote

Muses Labs Partners With Metabolon on Metabolomics of Cognitive Decline, Alzheimer's Disease

NEW YORK (GenomeWeb) – Muses Labs announced today that it has formed a partnership with Metabolon to research the metabolomics of pre- and early-symptomatic cognitive decline and Alzheimer's disease. 

Muses Labs currently markets a protocol called MEND for Alzheimer's disease, dementia, and related conditions. The methodology involves analyzing patients' genetic data and other medical information to identify the underlying pathways of their disorders and guide physician's treatment plans. 

Through its collaboration with Metabolon, Muses Labs said it plans to study metabolomics and apply it to the protocol, then develop and launch new clinical trial services this year. Specific terms of the arrangement were not disclosed.

"Metabolomics adds additional significant insight into a patient's biological status to improve identification of active pathologies and enable further refinement of patient care programs," Muses CEO Vik Chandra said in a statement. "Metabolomics has the potential to significantly expand the effectiveness of combination therapy protocols for Alzheimer's and other complex diseases."

Metabolon CEO John Ryals added that the partners aim to "use our proprietary technology in conjunction with Muses Labs' personalized protocols to provide clinicians with a more accurate health assessment of patients experiencing cognitive decline, as well as more actionable information."

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.